Broad agency announcement: fdavaa-19-00123-A3 " a systems-based approach to patient-focused research and product development"

Ended Definitive Contract Awarded Last action

Contract number
75F40119C10091
Awardee
Awarding agency
Obligated
$1,464,209

Award facts

Opportunity
  • 1220192 Solicitation number
Contract value 100% obligated
$1,464,208.71 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
NAICS code
813212 Voluntary Health Organizations
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Danbury, CT 06810, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00007 · The purpose of this modification is to change the buyer for invoicing purposes. All other terms and conditions remain unchanged. $0
Other Administrative Action P00006 · Modification to RE-OB funds to fix an IPP issue $450,381
Other Administrative Action P00005 · Modification to DE-OB funds to fix an IPP issue -$450,381
Other Administrative Action P00004 $0
Other Administrative Action P00003 · Modification to extend the period of performance through 09/15/2024 and add funding. $170,459
Other Administrative Action P00002 · Modification to extend the period of performance until 09/152022 for board agency announcement: fdavaa-19-00123-A3 " a systems-based approach to patient-focused… $0
Other Administrative Action P00001 · Modification to extend the period of performance until 09/16/2021 for board agency announcement: fdavaa-19-00123-A3 " a systems-based approach to… $0
Original award $1,293,750

About this award

Written by GovTribe AI ·

The National Organization For Rare Disorders Inc. (Nord), a non-profit organization, was awarded a $1,464,208.71 definitive cost plus fixed fee contract by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services. The contract, awarded on September 7, 2019, supports a systems-based approach to patient-focused research and product development related to rare diseases. The contract, which does not have a set-aside designation, runs through June 30, 2024. In addition to this prime contract award, Nord has received multiple federal grant subawards to provide various goods and services in support of rare disease research and drug development initiatives.

Quick answers

Who was awarded contract 75F40119C10091?

75F40119C10091 was awarded to The National Organization For Rare Disorders Inc. by Food and Drug Administration (Department of Health and Human Services) on September 7, 2019.

How much is contract 75F40119C10091 worth?

The government has obligated $1,464,209 on 75F40119C10091.

Was contract 75F40119C10091 competed?

The extent of competition for 75F40119C10091 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login